FDA approved drug administration for prevention of heart disease and stroke

[enterprise news of China Pharmaceutical network] recently, epatha (evolocumab), a drug approved by the U.S Food and drug administration, has become a PCSK9 inhibitor for the prevention of heart disease, stroke and coronary revascularization in adult patients with cardiovascular disease The reasons for approval come from the results of their clinical trials 27564 patients were selected for the clinical study of cardiovascular prognosis called Fourier According to the data, the risk of heart attack, stroke and coronary revascularization were reduced by 27%, 21% and 22% respectively Sean Harper, executive vice president of research and development of Amgen, said, "although the current treatment works well, many patients are still at high risk of cardiovascular events Through this approval, now there is a new treatment option, repatha, to prevent cardiovascular events and better reduce LDL cholesterol in the body, especially for those patients who have already tolerated statins to a large extent and still need to further reduce LDL cholesterol, which undoubtedly brings great help "   Repatha is a new PCSK9 inhibitor, which was approved by U.S regulators in 2015 to be used in combination with diet and large tolerance of statins for heterozygous familial hypercholesterolemia (hefh), homozygous familial hypercholesterolemia (hofh), or clinical atherosclerotic cardiovascular disease, such as heart attack or Stroke patients Repatha is a monoclonal antibody drug targeting to inhibit a protein called PCSK9, which can reduce the liver's ability to remove LDL-C from the blood LDL-C is recognized as a major risk factor for cardiovascular disease (CVD) PCSK9 inhibitors provide a new therapeutic mode to fight LDL-C, which is regarded as a great progress in the field of lipid-lowering after statins (such as Lipitor and Zocor) However, since repatha's entry into the market, monoclonal antibody drugs have been fiercely attacked by the consumer market (especially the United States) due to their high pricing (the annual treatment price is more than 14000 US dollars) These PCSK9 inhibitors are basically interchangeable on the market In order to win the market, major pharmaceutical companies will inevitably set off a price war, which can't help but remind people of the fierce battle between Gilead and Aberdeen in the field of hepatitis C treatment earlier this year Original title: FDA approved repatha for prevention of heart disease and stroke